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Abstract
Introduction: A new line probe assay, the GenoType® NTM DR, has been developed for subspecies
identification and detection of resistance to macrolides and aminoglycosides in clinical Mycobacterium abscessus
isolates. We studied the performance of the test compared to DNA sequencing and phenotypic drug susceptibility
testing (pDST).
Methods: 48 clinical M. abscessus isolates collected between 2015 and 2016 were identified to the subspecies
level and analysed for erm (41) genotype, rrl and rrs gene mutations by Sanger sequencing. Broth micro dilution was
performed for pDST of Clarithromycin and Amikacin. The results were compared to those of the GenoType® NTM
DR assay. Discordant results were further analysed by repeat pDST and whole genome sequencing (WGS).
Results: 35 isolates were identified as M. abscessus subsp. abscessus, 6 as M. abscessus subsp. bolletii, and 7
as M. abscessus subsp. massiliense based on rpoB sequences. Concordance of GenoType® NTM DR results with
Sanger sequencing was 92% for subspecies identification and 100% for erm (41), rrl, and rrs genotypes,
respectively. GenoType® NTM DR and pDST results matched in 98% for Clarithromycin resistance and in 96% for
Amikacin resistance when repeat pDST results were taken into account.
Conclusion: The new GenoType® NTM DR assay is a valuable test for subspecies identification of M.
abscessus isolates and detection of defined mutations conferring resistance to Amikacin and Clarithromycin.
Discrepancies between the line probe assay and pDST mainly relate to variations in phenotypic test results.
Keywords: M. abscessus; GenoType® NTM DR; Subspecies
identification; Resistance testing; Whole genome sequencing
Abbreviations: A: Adenine; Absc: M. abscessus subsp. Abscessus;
Boll: M. abscessus subsp. bolletii; C: Cytosine; G: Guanine; I:
Intermediate Resistance; INT: Interpretation; IR: Inducible Resistance;
Massil: M. abscessus subsp. Massiliense; MIC: Minimal Inhibitory
Concentration; MUT: Mutation; R: Resistant; Subsp.: Subspecies; S:
Susceptible; T: Thymine; WT: Wild Type.
Introduction
Mycobacterium abscessus is an emerging pathogen belonging to the
rapidly growing mycobacteria. The spectrum of disease includes
respiratory infections, especially in patients with chronic lung disease,
as well as skin, soft tissue and bone infections, and rarely disseminated
disease in severely immunosuppressed patients [1]. The M. abscessus
complex has recently been divided into three subspecies, M. abscessus
subsp. abscessus (or M. abscessus sensu strictu), M. abscessus subsp.
massiliense and M. abscessus subsp. bolletii [2-4]. Macrolides and
Amikacin are key drugs in the treatment of M. abscessus disease [1,5].
However, macrolide susceptibility varies by subspecies and may
explain the association between treatment outcomes and subspecies
[6-8]. The primary innate mechanism of macrolide resistance in M.
abscessus is the inducible expression of an erythromycin ribosomal
methylase, Erm(41). Erm(41) methylates the adenine at position 2058
of the 23S ribosomal RNA leading to reduced binding of macrolides to
their target site in the 50S ribosomal subunit [9]. M. abscessus subsp.
bolletii and M. abscessus subsp. abscessus harbour intact erm(41)
genes. However, a T/C polymorphism at position 28 in M. abscessus
subsp. abscessus results in inducible resistance (T28) or phenotypic
susceptibility (C28), respectively [10]. M. abscessus subsp. massiliense
has a dysfunctional erm(41) gene due to a 2 bp deletion of nucleotides
64–65 and a 274 bp deletion of nucleotides 159–432 leading to a
macrolide susceptible phenotype [9]. In addition, acquired high-level
resistance to macrolides is due to point mutations at positions 2058
and 2059 in the 23S rRNA (rrl) gene [11]. Acquired high-level
resistance to aminoglycosides is conferred by point mutations at
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position 1408 of the 16S rRNA (rrs) gene and can occur in all three
subspecies [12]. Today, subspecies identification and detection of
genetic resistance markers for M. abscessus are based on sequencing of
these specific target genes [13]. Recently a commercial line probe assay,
the GenoType® NTM DR (HAIN Lifescience, Nehren, Germany) has
been developed. It provides subspecies identification based on the
erm(41) gene variants, detection of point mutations in rrl and rrs, as
well as determination of the T/C 28 polymorphism of erm(41). This
study aimed to compare the GenoType® NTM DR assay with DNA
Sanger sequencing and phenotypic resistance results in isolates
obtained from patient samples, using whole genome sequencing
(WGS) to resolve discrepancies.
Materials and Methods
48 non-duplicate M. abscessus isolates obtained from the
respiratory tract (sputum, bronchial secretion, brocheoalveolar lavage,
n=34), blood (n=1), skin (n=1) or of unknown origin (n=13) were
included in the study. Strains were identified at the German National
Mycobacterium Reference Laboratory from July 2015 to January 2016
using the GenoType® CM assay (HAIN Lifescience, Nehren, Germany),
and Sanger sequencing of the 16S and rpoB genes using an ABI Prism
3100 capillary sequencer with BigDye Terminator v.1.1 chemistry
(Applied Biosystems, Foster City, CA) [14,15]. For subspecies
identification, rpoB sequences were compared with GenBank
accession numbers AY262741.1, AY593981.2 and AY859692.1 as
references.
All isolates were tested using the GenoType® NTM DR line probe
assay version 1.0 (HAIN Lifescience, Nehren, Germany) according to
the manufacturer’s instructions. DNA was extracted as described
elsewhere [16]. A senior scientist interpreted the results as per package
insert. Genotypic drug resistance was determined by sequencing of the
respective target genes erm(41) and rrl for macrolides, and rrs for
aminoglycosides (in resistant and discordant strains only) as described
previously [10,12].
Phenotypic drug susceptibility testing (pDST) was performed using
the broth microdilution method according to CLSI document M24-A2
on 96-well Thermo Scientific RAPMYCOI Sensititre plates (Thermo
Fisher Scientific, East Grinstead, UK) [17]. For inoculum preparation,
confluent growth on 7H10 agar plates was swept with a loop and
adjusted to a McFarland 0.5 turbidity standard in sterile water. Fifty
microliters of this suspension were added to 10 ml of Mueller-Hinton
broth and mixed; 100 µl of the final inoculum were transferred to each
well of a Sensititre plate. Colony counts were performed on 7H10
plates following 3-5 days of incubation to ensure correct inoculum
density (5 x 104 to 5 x 105 cfu/mL). Plates were sealed with adhesive
covers, incubated at 30°C and checked for sufficient growth in the
positive control well at day 3. In case of insufficient growth, plates were
reincubated and read at days 4 and 5, respectively. Additional readings
were performed at days 7 and 14 to detect inducible macrolide
resistance. The minimal inhibitory concentration (MIC) was defined as
the lowest drug concentration at which no visual growth was observed.
Clarithromycin resistance was defined as a MIC of ≥ 8 μg/ml,
susceptibility as a MIC ≤ 2 μg/ml, and Amikacin resistance was defined
as a MIC of ≥ 64 μg/ml, susceptibility ≤ 16 μg/ml [9,11]. Inducible
resistance for Clarithromycin was defined as MIC<8 ug/ml before day
5 and MIC ≥ 8 μg/ml after 7 or 14 days of incubation, respectively.
pDST was repeated for isolates with discordant pDST results
compared to the GenoType® NTM DR assay. Repeat pDST results were
used for the final comparison. WGS was performed for isolates with
unresolved discrepancies using Nextera library preparation and the
NextSeq sequencer (Illumina, San Diego). Reads were mapped to the
M. abscessus ATCC19977 genome (GenBank ID: NC_010397.1) with
the alignment program BWA and mappings refined with the GATK
and samtools toolkits. For variant detection in mapped reads, samtools
and perl scripts were employed to filter for variants called by at least
four reads in both forward and reverse orientation, with at least four
reads calling the allele with a phred score of 20 or more, and 75%
overall allele frequency. All discriminating variants were used for a
concatenated sequence alignment and a maximum parsimony
phylogenetic inference using BioNumerics v7.5 (Applied Maths,
Belgium). Additional reference strains for isolates with discordant
subspecies results were included in the analysis for a tree-based
phylogenetic classification (M. abscessus subsp. abscessus ATCC
19977T, M. abscessus subsp. bolletii CCUG 50184T and M. massiliense
CCUG 48898T). Sequence data were submitted to the ENA sequence
read archive (accession number ERP021910). Ethical approval was not
sought as a new test was evaluated against standard assays using
leftover samples already collected for clinical and laboratory
assessment. No additional information of patients was sought and no
patient contact was required. The results did not influence clinical
decision-making. Concordance of results was calculated comparing
proportions across different assays.
Results
Subspecies identification and initial drug susceptibility data of the
48 tested M. abscessus clinical isolates are summarised in Table 1.
Altogether, 11 discordant results were initially found comparing
GenoType® NTM DR to Sanger sequencing and pDST (isolate 5, 20,
21, 30–32, 34, 38–41).
  Clarithromycin Amikacin**
No Subsp NTM DR Sequencing pDST NTM DR pDST
 erm(41)T/C28 rrl Int
erm(41)
T/C28 rrl Int
MIC
d3-5 MIC d14 Int rrs Int
MIC
d3-5 Int
1 Absc T WT iR T WT iR 0,25 >16 iR WT S 8 S
2 Absc T WT iR T WT iR 0,06 >16 iR WT S 8 S
3 Absc C WT S C WT S 0,06 0,5 S WT S 8 S
Citation: Wassilew N, Hillemann D, Maurer FP, Kohl TA, Merker M, et al. (2017) Evaluation of the GenoType® NTM DR for Subspecies
Identification and Determination of Drug Resistance in Clinical M. abscessus Isolates. Clin Microbiol 6: 286. doi:
10.4172/2327-5073.1000286
Page 2 of 6
Clin Microbiol, an open access journal
ISSN:2327-5073
Volume 6 • Issue 4 • 1000286
4 Absc1 T WT iR T WT iR 0,25 >16 iR WT S 8 S
5 #Absc T A2058G R T A2058G R 1 >16 iR A1408G R >64 R
6 Absc T WT iR T WT iR 0,12 >16 iR WT S 16 S
7 Absc T WT iR T WT iR 0,06 >16 iR WT S 4 S
8 Absc T WT iR T WT iR 0,25 >16 iR WT S 8 S
9 Absc T WT iR T WT iR 0,12 >16 iR WT S 8 S
10 Absc T WT iR T WT iR 0,12 >16 iR WT S 16 S
11 Absc T WT iR T WT iR 0,06 16 iR WT S 8 S
12 Absc2 C WT S C WT S 0,06 0.12 S WT S 4 S
13 Absc T A2058C R T A2058C R >16 >16 R A1408G R >64 R
14 Absc T WT iR T WT iR 0,5 >16 iR WT S 8 S
15 Absc T WT iR T WT iR 0,12 >16 iR WT S 8 S
16 Absc T WT iR T WT iR 0,06 >16 iR WT S 8 S
17 Absc T WT iR T WT iR 0,25 >16 iR WT S 8 S
18 Absc T WT iR T WT iR 0,12 >16 iR WT S 8 S
19 Absc T WT iR T WT iR 0,12 >16 iR WT S 8 S
20 #Absc T WT iR T WT iR 0,25 1 S WT S 8 S
21 #Absc1 T WT iR T WT iR 0,12 2 S WT S 8 S
22 Absc T WT iR T WT iR 0,06 >16 iR WT S 4 S
23 Absc T WT iR T WT iR 0,12 >16 iR WT S 4 S
24 Absc T WT iR T WT iR 0,06 >16 iR WT S 4 S
25 Absc T WT iR T WT iR 0,5 >16 iR WT S 8 S
26 Absc C WT S C WT S 0,06 0.5 S WT S 4 S
27 Absc C WT S C WT S 0,06 0.25 S WT S 8 S
28 Absc T WT iR T WT iR 0,06 >16 iR WT S 4 S
29 Absc2 C WT S C A2057C ? 0,06 1 S WT S 8 S
30 #Absc T WT iR T A2057G ? 0,12 >16 iR WT S >64 R
31 #Absc T WT iR T A2057G ? 0,12 >16 iR A1408G R 8 S
32 #Boll T WT iR T WT iR 0,5 >16 iR WT S 64 R
33 Boll T WT iR T WT iR 0,25 >16 iR WT S 16 S
34 #Boll T WT iR T WT iR 0,06 4 I WT S 8 S
35 Boll T WT iR T WT iR 0,06 >16 iR WT S 8 S
36 Boll T WT iR T WT iR 0,12 >16 iR WT S 2 S
37 Boll T WT iR T WT iR 0,5 >16 iR WT S 2 S
38 Massil* T WT S T WT S 0,12 0.5 S WT S 8 S
39 Massil* T WT S T WT S 0,12 0.5 S WT S 8 S
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40 Massil* T WT S T WT S 0,06 0.25 S WT S 8 S
41 Massil* T WT S T WT S 0,06 1 S WT S 4 S
42 Massil T WT S T WT S 0,06 0,06 S WT S 16 S
43 Massil T A2058C R T A2058C R >16 >16 R A1408G R >64 R
44 Massil T A2058G R T A2058G R >16 >16 R WT S 8 S
45 Massil T A2058C R T A2058C R >16 >16 R A1408G R >64 R
46 Massil T A2058C R T A2058C R >16 >16 R A1408G R >64 R
47 Massil T A2058C R T A2058C R >16 >16 R A1408G R >64 R
48 Massil T WT S T WT S 0,06 0.5 S WT S 8 S
*: Discordances in subspecies differentiation between Sanger sequencing (M. abscessus subsp. abscessus) and GenoType® NTM DR (M. abscessus subsp.
massiliense);
**: The rrs gene was sequenced for all isolates showing resistance to Amikacin (Mut1–A1408G) or discordance between pDST and GenoType® NTM DR results.
1,2: same patient;
#: Discordances in initial pDST results (Clarithromycin and/or Amikacin).
Repeat pDST for respective isolates:
Clarithromycin, MIC d3-5/d14, μg/ml, Int: Isolate No. 5: 1/>16, iR; isolate No. 20: 0.25/>16, iR; isolate No.21: 0.12/>16, iR; isolate No. 34 0.06/2, S
Amikacin, MIC d3-5, μg/ml, Int: Isolate No. 30: >64, R; isolate No. 31: >64, R; isolate No 32: >64, R.
Table 1: GenoType® NTM DR, sequencing and first phenotypic drug susceptibility testing (pDST) results for clarithromycin and amikacin.
Subspecies identification by Sanger sequencing revealed 35 M.
abscessus subsp. abscessus, six M. abscessus subsp. bolletii and seven
M. abscessus subsp. massiliense isolates. There was concordance of
92% (44/48) between Sanger sequencing and GenoType® NTM DR
results. The four discordant isolates (isolates 38-41) were identified as
M. abscessus subsp. abscessus by rpoB sequencing and as M. abscessus
subsp. massiliense using the GenoType® NTM DR assay. WGS was
performed on these isolates, confirming GenoType® NTM DR
subspecies identification for all four isolates.
Sanger sequencing and GenoType® NTM DR showed 100% (48/48)
agreement for the erm(41) T/C28 polymorphism and 100% (48/48) for
analysis of rrl positions 2058 and 2059. For three isolates (isolates
29-31) Sanger sequencing revealed a mutation at position 2057,
replacing adenine with guanine in two isolates and adenine with
cytosine in one isolate. The pDST results for Clarithromycin were in
accordance with the results predicted by GenoType® NTM DR
(susceptible in isolate 29, and inducibly resistant in isolates 30 and 31).
GenoType® NTM DR results for Clarithromycin were concordant
with initial pDST results in 94% (45/48). Repeat pDST of two M.
abscessus subsp. abscessus isolates (isolates 20 and 21), previously
tested susceptible, showed inducible resistance in concordance with
both the GenoType® NTM DR and the sequence of erm(41). Repeat
pDST of the third isolate (M. abscessus subsp. bolletii, isolate 34),
initially tested intermediate (MIC 4 μg/ml at day 14), showed
susceptibility (MIC 2 μg/ml at day 14). GenoType® NTM DR and
Sanger sequence data for position 28 of the erm(41) gene (thymine)
indicated inducible resistance for this isolate. WGS of isolate 34
revealed several amino acid exchanges within the erm(41) gene. No
frameshifts or deletions were observed.
Three of the 48 isolates showed discordant results for Amikacin
between GenoType® NTM DR and initial pDST. Repeat pDST resolved
one of the discrepancies (isolate 31, initially falsely susceptible in
pDST). Two isolates (isolate 30 and 32) were repeatedly tested resistant
to Amikacin (MIC>64 μg/ml), with rrs position 1408 being wildtype in
both GenoType® NTM DR and Sanger sequencing. WGS showed no
mutation across the whole rrs gene for isolate 34, and two mutations at
rrs positions 1305 (adenine to cytosine) and 1306 (thymine to adenine)
in isolate 32.
Discussion
In this study, results of the GenoType® NTM DR assay and Sanger
DNA sequencing were concordant in 92% for subspecies
differentiation, in 100% for the erm(41) T/C28 nucleotide
polymorphism, in 100% for rrl positions 2058 and 2059, and in 100%
for rrs position 1408 (in isolates showing resistance to Amikacin or
discordant pDST results). GenoType® NTM DR showed concordance
with pDST in 94% for Clarithromycin resistance and in 94% for
Amikacin resistance, improving to 98% and 96%, respectively, after
repeat pDST. Similar results have recently been published by
Kehrmann et al. [18] and Mougari et al. [19], however discordance of
subspecies identification or resistance results did not take into account
WGS data.
Four isolates (isolates 38-41) were identified as M. abscessus subsp.
abscessus by sequencing of the rpoB gene alone, but as M. abscessus
subsp. massiliense by GenoType® NTM DR, differenciating the
subspecies on the basis of the erm(41) gene variants, and WGS. All
four isolates displayed Clarithromycin susceptibility patterns
compatible with M. abscessus subsp. massiliense (susceptible on days 3
and 14) and an erm(41) sequence showing the characteristic deletions
of nucleotides 64–65 and 159–432. This has been described by others
[20] and reflects the uncertainty of subspecies differentiation for M.
abscessus when using a single gene like rpoB. Here, WGS can be of
advantage as it allows more accurate assessment of an individual
isolate in comparison to reference genomes of all three M. abscessus
subspecies. The importance of subspecies identification for clinical
practice is still a matter of debate. Some studies investigating the
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association between subspecies identification and treatment outcomes
in patients with pulmonary disease found better results for M.
abscessus subsp. massiliense [6,7]. Whether improved treatment
outcomes are due to decreased virulence of M. abscessus subsp.
massiliense or the non-functional erm(41) gene (linked to macrolide
susceptibility) is unclear. However, M. abscessus subsp. massiliense has
also been associated with transmission among patients with cystic
fibrosis [21]. If indeed M. abscessus subsp. massiliense is more
transmissible, correct subspecies identification would also be
important for infection control purposes.
While concordance between genotypic and phenotypic
susceptibility testing was generally high, two functional erm(41) genes
and one rrs mutation were detected in three independent M. abscessus
subsp. abscessus isolates (isolates 20, 21, 31), though initial pDST
showed susceptibility. Repeat pDST revealed resistance for all three
isolates. This finding indicates that discrepancies between genetic and
phenotypic susceptibility testing of M. abscessus often relate to
problems of poor growth and difficulties in interpreting MICs, and not
to errors in genetic assays [22].
One M. abscessus subsp. bolletii isolate with a functional erm(41)
gene (isolate 34) showed intermediate resistance to Clarithromycin
(MIC 4 μg/ml) on initial and susceptibility (MIC 2 μg/ml) on repeat
pDST. Possible explanations include poor growth or difficulties in MIC
interpretation. WGS for this isolate showed several point mutations
within the erm(41)gene. Similar WGS results were observed for two
other M. abscessus subsp. bolletii isolates, but the mutations were
different in these strains. Whether the mutations in isolate 34 led to a
dysfunctional erm(41) gene remains unknown and would need further
evaluation.
Interestingly, we observed three independent M. abscessus subsp.
abscessus isolates with an A2057G mutation in the rrl gene (isolates
29-31). As rrl positions 2058 and 2059 were wildtype and pDST for
Clarithromycin did not show resistance on days 3-5, genotypic and
phenotypic test results were considered concordant. However, this
rarely occurring mutation has previously been described as conferring
medium to low level resistance to Clarithromycin in M. abscessus
(MIC 8 μg/ml) [13,23]. Further studies are needed to reveal the
significance of this point mutation in clinical M. abscessus isolates. For
one of the isolates (isolate 29), another isolate from the same patient
didn’t show this mutation (isolate 12), which could be indicative for a
mixed M. abscessus population.
Two isolates (isolates 30 and 32) without evidence of any mutations
in the rrs gene as determined by the GenoType® NTM DR assay and
Sanger sequencing were repeatedly resistant to Amikacin by pDST.
WGS revealed point mutations at positions 1305 and 1306 of the rrs
gene in one of the two isolates. Whether this mutation confers
resistance to aminoglycosides is currently unknown. WGS did not find
any mutation of the rrs gene in the second isolate. Other mechanisms
such as changes in cell wall permeability might lead to Amikacin
resistance and explain these results [24].
Macrolides and Amikacin are the cornerstones of M. abscessus
treatment regimens if the isolate is susceptible [1,5]. Furthermore,
macrolides are often the only oral therapeutic option for M. abscessus
disease. As the recommended treatment duration is 12 months
following culture conversion, adverse events associated with therapy
are common [1,5]. In our hands, the GenoType® NTM DR allowed
rapid subspecies identification and accurate determination of
mutations conferring resistance to Clarithromycin and Amikacin. As
such, the assay can readily be implemented in a routine laboratory. The
clinical relevance of the results and the potential advantages over pDST
remain a matter of debate. However, early knowledge about acquired
aminoglycoside or macrolide resistance allows rapid and more rational
design of therapeutic regimens, prevention of unnecessary drug
toxicity and more transparent patient communication. The rapidity of
the results compared to pDST might be an advantage for a certain
patient population. We believe this actively enhances patient
experience and control in decision-making [25].
An inherent drawback of line probe assays such as the GenoType®
NTM DR is their limitation to testing known mutations conferring
phenotypic resistance. In contrast, pDST allows detection of resistance
regardless of the underlying mechanism. This is particularly important
when determining susceptibility for M. abscessus as resistance is not
exclusively due to mutations, but may result from other mechanisms
such as upregulated drug export systems or decreased cell wall
permeability [26]. On the other hand, pDST interpretation can be
difficult for rapidly-growing mycobacteria as poor growth can lead to
falsely susceptible results [22]. In this case GenoType® NTM DR can
help to improve the interpretation of pDST results by supporting or
refuting them. In fact, parallel susceptibility testing using pDST and
the GenoType® NTM DR appears to be useful to ensure consistency
across methods.
This study has several limitations. The sample size (48 isolates from
46 patients) was small. Isolates sent to a National Reference Laboratory
are likely to be pre-selected and therefore results might not be
generalizable. Clinical information was available for few isolates,
precluding any meaningful analysis of clinical data. Diagnostic gold
standards for M. abscessus are lacking as both genetic and phenotypic
susceptibility testing methods possess the intrinsic limitations
mentioned above. Thus sensitivity and specificity as well as predictive
values of the GenoType® NTM DR were not assessed.
Our current knowledge of M. abscessus disease is incomplete. New
molecular diagnostic tools such as the GenoType® NTM DR will allow
rapid and accurate subspecies differentiation and determination of
genetic resistance markers. Although they cannot replace pDST, they
can support the interpretation of pDST data, guide treatment, and
enhance our understanding of M. abscessus as an emerging pathogen.
Finally, a reliable diagnostic workflow integrating both genotypic and
phenotypic methods will support the execution of urgently needed
clinical studies correlating in vitro drug susceptibility data to clinical
outcome.
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